Nucorion Pharmaceuticals, Inc.
Records under this name other than the patents Nucorion Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Showing 1 to 4 of 4 · Back to Nucorion Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,059,733 | Gemcitabine Analogs Formerly held Lapsed on the fee record Ended Aug 28, 2022 · High confidence | Lapsed on the fee record | Ended Aug 28, 2022 | High confidence |
| US 10,000,521 | Substituted Gemcitabine Bicyclic Amide Analogs and Treatment Methods Using Same Formerly held Lapsed on the fee record Ended Jun 19, 2022 · High confidence | Lapsed on the fee record | Ended Jun 19, 2022 | High confidence |
| US 9,744,186 | Substituted Gemcitabine Aryl Amide Analogs Formerly held Lapsed on the fee record Ended Aug 29, 2021 · High confidence | Lapsed on the fee record | Ended Aug 29, 2021 | High confidence |
| US 9,447,137 | Substituted Gemcitabine Aryl Amide Analogs Formerly held Lapsed on the fee record Ended Sep 20, 2020 · High confidence | Lapsed on the fee record | Ended Sep 20, 2020 | High confidence |